This meta-analysis of rosiglitazone and cardiovascular events appeared on the NEJM website some weeks ago, and few readers with an interest in diabetes can have failed to read something or other about it, or even the paper itself. I think most people will find it extraordinarily difficult to analyze. […]
NEJM 14 Jun 2007 Vol 356
